Zenas BioPharma

Nearly five years after its first approval for neuromyelitis optica spectrum disorder (NMOSD) in June 2020, the US Food and Drug Administration approved Amgen’s Uplizna (inebilizumab) to treat adults

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t

BioAge Labs, Inc. switched the development focus for its lead drug candidate, the small molecule apelin receptor (APJ) agonist azelaprag, from age-related muscle loss to prevention of muscle loss in

Stock market listings were back on the upswing last quarter, with the eight biotechs floating on Western exchanges raising a total of $1.1bn. In fact, there seems to have been a bit of a rush: three c